ArticleIn silico pharmacology2025
Inhibition of IRF3-STING axis interaction in silicosis using natural compounds: an in-silico study using molecular docking, ADMET, molecular dynamics and MMPBSA approach.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In silico evaluation of anticancer peptide as a novel therapeutic agent against AURKA for targeting oral carcinogenesis.Journal of molecular modeling · 2025Article
- The cGAS-STING axis: a comprehensive review from immune defense to disease pathogenesis.Immunologic research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silicosis is a chronic occupational lung disease characterized by persistent inflammation driven by the activation of the cGAS-STING pathway, leading to the downstream activation of IRF3. To develop a natural compound library of COCONUT database for this investigation, Lipinski's rule of five was used and we explored the potential of these compounds to disrupt the IRF3-STING interaction, thereby mitigating the inflammatory response. Molecular docking and molecular dynamics (MD) simulations were employed to assess the binding stability and interaction dynamics of these compounds with IRF3. The stable RMSD values indicate that the protein-ligand complexes maintained structural integrity throughout the simulation period. The compounds also demonstrated drug-like characteristics, a promising safety profile, and formed stable complexes with the target protein. Further, decomposition of binding free energy highlighted the key contributions of IRF3 residues VAL295, ASP308, PRO324, and ARG338 interacting with the selected compounds, potentially inhibiting the IRF3-STING interaction. The origin of the selected compounds was determined using ClassyFire, classifying compound CNP0310627 as a burfenolide and compound CNP0200121 as a psoralen. Both classes are recognized for their anti-inflammatory properties, reinforcing the therapeutic potential of these compounds in reducing inflammation associated with silicosis. Our findings suggest that these compounds could serve as promising candidates for further investigation in the development of anti-inflammatory therapeutic molecules in the cGAS-STING-IRF3 signaling pathway. However, to fully assess the therapeutic potential of these compounds, further in vitro and in vivo studies are required to validate their efficacy and safety in modulating the STING-IRF3 pathway. Graphical abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-024-00290-5.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.